News archive
Showing 688 results
November 2017
-
Media Release
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
- Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association… -
Media Release
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
-
Media Release
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
- Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-… -
Media Release
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
-
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
- Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study(1)- PsA can lead to reduced mobility… -
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
-
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
- Primary results of pivotal Kymriah™ Phase II JULIET study in relapsed/refractory DLBCL- Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickle… -
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
October 2017
-
Media Release
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
- PARADIGMS data also show fingolimod-treated patients had significantly fewer new brain lesions vs. those on intramuscular interferon beta-1a injections(1)- Currently there are no disease-modifying… -
Media Release
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
-
Media Release
Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
- "Hope" is inspired by the psoriasis community and Lauper's own experience living with the disease- Song and music video are available to stream at SEEMEtoknow.com- An estimated 7.5 million people… -
Media Release
Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day